Introduction
-Opioid receptors (OP 3 receptor, NC-IUPHAR recommended nomenclature) are coupled to several transduction mechanisms via activation of guanine nucleotide-binding (G i /G o ) proteins. G-protein coupled receptors have been shown to adapt to the chronic presence of agonists in a process that involves desensitization (functional uncoupling of the receptors from signal-transducing G-proteins) and/or receptor downregulation (internalization and/or net loss of receptor protein).
Repeated opioid administration leads to tolerance and dependence phenomena but the molecular and cellular mechanisms governing these adaptations are still uncertain, though desensitization and receptor down-regulation are believed to play an important role. 1, 2 Thus, chronic exposure of cultured cells to opioids results in -opioid receptor down-regulation and desensitization (for a review, see [3] [4] [5] [6] [7] [8] ) whereas the studies of chronic opioid administration in rodents or humans reveal, in general, no change in opioid receptor density and/or activity (for a review, see 3, 6, [8] [9] [10] [11] ). Therefore, the cellular basis of opioid tolerance and dependence may involve homeostatic adaptations at the postreceptor level 2 and/or regulation of other Gprotein coupled receptors sharing common activities with -opioid receptors. 4, 9, 12 Morphine administration produces hypoactivity of noradrenergic cells within the locus coeruleus, whereas the withdrawal from chronic morphine treatment results in hyperactivity of these neurons. 2, 13 The noradrenergic neurons of the locus coeruleus can also be inhibited by ␣ 2 -adrenoceptor agonists through receptor-signal transduction mechanisms shared with -opioid receptors.
14 Currently, there is substantial evidence indicating that administration of ␣ 2 -adrenoceptor agonists normalizes the central noradrenergic hyp-eractivity associated with the opioid withdrawal syndrome. 13, 15 Adaptive changes of ␣ 2 -adrenoceptor density in brain have been demonstrated in animal models of opioid dependence 9, 12 and in human heroin addicts 3 Such adaptations suggest that down-regulation of presynaptic ␣ 2 -adrenoceptors (autoreceptors) in brain cortex could represent a compensatory mechanism to overcome the decrease of norepinephrine release induced by the hypoactivity of noradrenergic neurons following chronic opioid administration. 16 However, despite the existence of information on the biochemical status of brain ␣ 2 -adrenoceptors in heroin addicts, 3 no data on the functional activity of these receptors during opioid dependence in humans has yet been published.
The [ 35 S]GTP␥S binding assay has been developed as a functional method to assess the receptor-mediated activation of G-proteins in isolated membranes and histological sections. 17 The binding of the radiolabeled non-hydrolizable GTP analogue [ 35 
S]GTP␥S measures the exchange of GDP for GTP (or [
35 S]GTP␥S) on the Gprotein and in this way it reflects directly the receptor activation induced by different agonists. 18, 19 The technique has been successfully applied to evaluateopioid receptor desensitization in cultured cells 7 and rat brain preparations. 6, 10 Recently, we have demonstrated the applicability of the [
35 S]GTP␥S binding assay to human brain membrane homogenates and sections in spite of the limitations inherent to postmortem tissue preparations. 20, 21 The present study has used the [ 35 S]GTP␥S binding assay to provide direct functional information on the status of receptor-G-protein coupling in brain of chronic opioid-dependent subjects. The ability of the -opioid receptor agonist DAMGO and the ␣ 2 -adrenoceptor agonist UK14304 to activate G-proteins was assessed in postmortem frontal cortices of opioid addicts and matched controls.
Subjects and methods

Brain samples
Postmortem human brain samples were obtained at autopsy from the Institutes of Forensic Medicine, Geneva, Switzerland, and Bilbao, Spain.
Specimens of prefrontal cortex (Brodmann area 9) were obtained from 15 male subjects who had died of an opioid overdose as determined by the medical examiner, and they were stored at −70°C (Table 1) . Drug screening in blood samples confirmed the presence of fatal concentrations of morphine or methadone in all the subjects (Table 1) . Generally, it is assumed an average serum concentration of over 0.4 g ml methadone is sufficient to cause death in subjects tolerant to opioids. 22 In blood specimens of heroin-related deaths, a mean concentration of 0.22 g ml −1 morphine has been found to be lethal. 23 The determination of a long-term history of opioid addiction was made by the medical examiner on the basis of: (1) the presence of opioid and/or opioid metabolites on toxicological screenings in blood, urine, and scalp hair; (2) the polMolecular Psychiatry ice reports following interviews with family members; and (3) the medical histories of the subjects when available. Most of these subjects had been used in previous studies, which revealed marked alterations of specific brain markers related to opioid addiction. 11, 24, 25 Ethanol (0.66 ± 0.22 g L −1
; seven subjects) and/or benzodiazepines (three subjects) were also found in blood samples. Subjects who gave a positive toxicological presence at death of cocaine, cocaine metabolites, amphetamine or amphetamine derivatives were excluded from the study. The retrospective searching of data and the detection of opioid, metabolites and/or other drugs in hair samples (3 cm from the root gives information on drug abuse within 6-12 months before death) also allowed the study to be restricted to those polydrug abusers who had been exposed mainly to chronic opioids (Table 1 ). In most opioid addicts (n = 9), the detection of the heroin metabolite 6-monoacetylmorphine (range 0.2-4 ng mg ) in hair samples indicated a long-term abuse of opioids in these subjects. The toxicological screenings were performed at the Toxicology Unit, Institute of Forensic Medicine, Geneva, Switzerland, and at the Instituto Nacional de Toxicologia, Madrid, Spain, using standard procedures. 3, 26 Control specimens were obtained at autopsy from potential control subjects dying in the same period and who met the following criteria: (1) sudden and unexpected death (motor vehicle accidents, cardiac arrest); (2) appropriate age, sex, and postmortem delay to match each subject in the opioid addict group; (3) absence of an apparent history of neuropsychiatric disorder or drug abuse; and (4) negative toxicological screening with the exception of ethanol (Table 2 ). Ethanol was found in blood samples from four subjects (1.5 ± 0.5 g L −1 ) of the control group, but evidence that these subjects were not ethanol dependents was obtained. The definitive control group consisted of specimens from 15 male subjects with an age at death, a postmortem delay and a tissue storage period that did not differ between opioid addicts (Table 1) and controls (Table 2) .
[ 35 S]GTP␥S binding assays
The membrane preparation and the [
35 S]GTP␥S binding assay were performed as reported in detail previously. 20 Briefly, cortical tissues were homogenized in an ice-cold Tris buffer (50 mM Tris HCl, 3 mM MgCl 2 , 1 mM DTT, 1 mM EGTA, pH 7.4) containing 0.25 M sucrose and membrane P 2 fractions were prepared by sequential centrifugations and resuspensions in Tris buffer. Final aliquots were stored at −70°C for binding assays and protein determination.
After thawing, 80 g ml −1 of membrane proteins were incubated at 30°C for 2 h in incubation buffer (50 mM Tris HCl, 3 mM MgCl 2 , 0.2 mM DTT, 1 mM EGTA, 100 mM NaCl, 50 M GDP, pH 7.4) containing 0.5 nM [ 35 S]GTP␥S. The -opioid receptor agonist DAMGO (10 −10 -10 −4 M) or the ␣ 2 -adrenoceptor agonist UK14304 (10 −9 -10 −3 M) was added to determine receptor-stimu- Group values are mean ± SEM of 15 men. Methadone (Met), morphine (Mor), codeine (Cod), ethanol and other drugs were quantified in blood samples. In two cases the presence of morphine in blood was made by qualitative methods. Therapeutic concentrations of benzodiazepines were also detected in some subjects. The postmortem delay represents the time period from death to the storage of the brain specimens. Group values are mean ± SEM of 15 men. The number (first column) indicates the control subject that was matched with each opioid addict identified with the same number in the addict group (first column in Table 1 ). Toxicological screening was similar to that performed in opioid addicts and included ethanol, opioids and other drugs. The postmortem delay represents the time period from death to the storage of the brain specimens. 
Results
The basal binding of [
35 S]GTP␥S to cortical brain membranes in opioid addicts was not significantly different from that in matched controls (t = 0.74; df = 28; P = 0.46) ( Table 3) . Because of the expected variability in basal values among individual assays (Figure 1) , the data were further evaluated by an analysis of covari- The -opioid receptor agonist DAMGO (10
]GTP␥S binding to cortical membranes in a concentration-dependent and saturable manner with maximal stimulations of 62 ± 8% in opioid addicts and 60 ± 12% in controls (Figure 2a) . The maximal net stimulation (E max in fmol mg −1 of protein) induced by DAMGO was also similar in both groups of subjects (Table 3 ). The EC 50 values of the concentration-response curves were in the micromolar range (Table 3 ) and they did not differ between opioid addicts and controls (log EC 50 values: t = 0.94; df = 28; P = 0.35). The mean concentration-response curve to DAMGO in opioid addicts was almost superimposed to that in controls (Figure 2a) indicating the absence of desensitization of this -opioid receptor-mediated functional response (receptor/G-protein coupling) in chronic opioid abusers.
The functional status of ␣ 2 -adrenoceptors was also assessed in the same membrane preparations from opioid addicts and matched controls. The [
35 S]GTP␥S binding stimulation through ␣ 2 -adrenoceptors was conducted with UK14304, a selective full agonist drug. UK14304 (10 −9 -10 −3 M) stimulated the [ 35 S]GTP␥S binding to cortical membranes in a concentrationdependent and saturable manner with similar maximal stimulations in opioid addicts (28 ± 3%) and control subjects (32 ± 8%) (Figure 2b) . Similarly, there were no differences between both groups of subjects in the maximal net stimulation (E max in fmol mg −1 of protein) of the [ 35 S]GTP␥S binding induced by UK14304 (Table 3 ). In contrast, the EC 50 values of the concentration-response curves were clearly increased (10-fold) in opioid addicts when compared with controls (Table 3 ) (log EC 50 values: t = 2.91; df = 28; P = 0.007). The mean concentration-response curve to UK14304 in opioid addicts was rightward shifted with respect to that in controls (Figure 2b) , indicating a desensitization of this functional response (coupling to G-protein) mediated by ␣ 2 -adrenoceptors in opioid addicts. Tables 1 and 2 . The curves represent the mean concentrationresponse isotherms obtained from the simultaneous analysis of all the experiments together in each group. Absolute basal values were similar in both groups and are expressed in Table 3 . Note that in opioid addicts (᭹), the [ 35 S]GTP␥S binding stimulation by DAMGO was not altered whereas that of UK14304 was markedly rightward shifted with respect to controls.
To evaluate a possible influence of the type of opioid agonist present at death in blood samples, [ 35 S]GTP␥S binding parameters were compared between subjects with blood presence of morphine and subjects with blood presence of methadone ( . In a similar manner, the maximal net stimulations induced by the agonists DAMGO and UK14304 and their EC 50 values were also found unchanged between both opioid addict subgroups (data not shown).
The subgroup of opioid addicts in whom the presence in blood of other drugs than opioids including ethanol was negative (n = 6; Table 1 ) was compared with the subgroup of control subjects in whom the absence of ethanol in blood samples was established (n = 11; 
Discussion
The present findings provide direct information on the functional status of -opioid receptors and ␣ 2 -adrenoceptors in postmortem brain of opioid addicts. The results of the study indicate a lack of desensitization in the [
35 S]GTP␥S binding stimulation by the -opioid receptor selective agonist DAMGO in cortical brain membranes from chronic abusers of opioids. In contrast, the decreased potency of the selective ␣ 2 -adrenoceptor agonist UK14304 to stimulate [
35 S]GTP␥S binding in the same membrane preparations indicates the evidence of a marked desensitization of ␣ 2 -adrenoceptors during opioid dependence in humans. The data reported herein represent a functional confirmation of previous findings obtained in brain of opioid addicts by receptor radioligand binding studies (ie, unaltered density of -opioid receptors and decreased density of ␣ 2 -adrenoceptors). 3 The quantification of [ 35 S]GTP␥S binding in postmortem human brain and its stimulation by selective receptor agonists represents a powerful technique to evaluate the activity of G-proteins (basal values) and the receptor ability to activate the nucleotide exchange on these G-proteins (mainly G i /G o -proteins in brain, see below). 20 Basal [ 35 S]GTP␥S binding in cortical brain membranes was not different between opioid addicts and controls (Table 3 ; Figure 1) suggesting normal functioning in G-protein basal activity. This unaltered basal activity in brains of opioid addicts is at variance with the increased immunoreactivities of G ␣1/2 -, G ␣o -, and G ␣s -proteins observed in postmortem frontal cortex of heroin addicts 26 and the decrease of G ␣1/2 -protein density obtained in platelets of methadone-maintained subjects. 28 However, it should be noted that measurements of G-protein levels may not provide accurate estimates of functional activity of these proteins. In fact, a similar dissociation between basal [
35 S]GTP␥S binding activity and G i /G o -protein immunoreactivities can be observed in the rat brain after chronic morphine treatment. 6, 29, 30 Despite the fact that [ 35 S]GTP␥S binding signal does not discriminate among the different Gproteins, the existence of compensatory changes between G i /G o -proteins and other G-proteins seems unlikely to explain the absence of changes in basal Chronic treatment of rats with morphine has been shown to result in decreased G-protein activity, as measured by basal [
35 S]GTP␥S binding, restricted to the locus coeruleus whereas other brain areas (cortex, basal ganglia, hypothalamus, amygdala) did not show apparent changes. 6, 10 The present findings in the frontal cortex of opioid addicts are similar to those obtained in the cerebral cortex of morphine-dependent rats. 10 Whether or not changes in G-protein basal activity also occur in the locus coeruleus of opioid addicts remains unknown. However, the changes in Gproteins induced by chronic morphine in rodents and by the long-term abuse of opioid in humans 11, 26, [30] [31] [32] do not seem to be restricted to those G-proteins within the locus coeruleus as initially found. 29 The ability of the -opioid receptor agonist DAMGO to stimulate the binding of [
35 S]GTP␥S to cortical membranes was similar in opioid addicts and control subjects (Table 3 ; Figure 2a ). This finding indicates a lack of desensitization or uncoupling of -opioid receptors from G-proteins in brain of chronic opioid abusers. This agrees well with previous data reporting thatopioid receptor agonist binding ( The issue of -opioid receptor regulation in experimental models of chronic opioid administration has produced a voluminous literature with apparent contradictory data reporting down-regulation, up-regulation, or no changes of biochemical and functional receptor parameters (see [3] [4] [5] [6] [7] [8] [9] and references therein). Differences in exposure time, dose, type of opioid drug, route of administration, tissue, and assay conditions could account for such discrepancies. Furthermore, the absence of conclusive changes in -opioid receptor density and functional coupling to G-proteins could be explained by the development of compensatory responses, at the postreceptor level, to the sustained effect exerted by the chronic presence of the opioid drug. Thus, up-regulation of the cAMP system is a well established cellular adaptation that overcomes in selected brain areas the inhibitory effect of opioids on this transduction system. 1 Alternatively, homeostatic changes in other transduction systems of -opioid receptors (K + and Ca 2+ channel conductance, mitogenactivated protein kinase pathway) might also occur. 2 On the other hand, the heterologous desensitization of other brain receptors sharing common coupling systems and cellular locations with -opioid receptors Molecular Psychiatry should be taken into account as a possible in vivo mechanism underlying tolerance and dependence. 4 In contrast to responses mediated by -opioid receptors, the [ 35 S]GTP␥S binding stimulation by the ␣ 2 -adrenoceptor agonist UK14304 showed a clear desensitization in the postmortem frontal cortex of the same opioid addicts (Table 3; Figure 2b ). This result represents a functional demonstration that the down-regulation of ␣ 2 -adrenoceptor agonist binding sites ([ 3 H]clonidine binding) previously observed 3 constitutes a relevant biochemical adaptation during the development of opioid dependence in humans.
Noradrenergic neurons in the CNS possess both ␣ 2 -adrenoceptors and -opioid receptors sharing effector mechanisms of transduction.
14 In brain cortex, ␣ 2 -adrenoceptors and -opioid receptors are colocalized as inhibitory receptors on noradrenergic terminals arising from the locus coeruleus. 33 Cross tolerance between opioids and ␣ 2 -adrenoceptor agonists has been clearly demonstrated in several tests. 12, [34] [35] [36] [37] It has also been shown that chronic morphine administration in rats decreases the density of brain ␣ 2 -adrenoceptors. 9, 12 Therefore, the down-regulation and functional desensitization of ␣ 2 -adrenoceptors appears to be one of the adaptive mechanisms that would tend to overcome the decreased function of noradrenergic pathways during chronic administration of opioids. 16, 38 This type of heterologous desensitization may play the functional role of a tolerance mechanism in brain areas such as the frontal cortex where the -opioid receptor population remains resistant to down-regulation during chronic opioid administration.
In the human frontal cortex, the ␣ 2 -adrenoceptor population appears to be predominantly of the ␣ 2A -subtype. 39, 40 The ␣ 2A -adrenoceptor also appears to be the autoreceptor that regulates the release of norepinephrine in the human frontal cortex. 41 Therefore, the results of this study indicate that subsensitivity of ␣ 2A -adrenoceptors plays a major regulatory role during opioid dependence in humans.
Taking all the previous points together makes it tempting to speculate that ␣ 2 -adrenoceptor (and/or other brain receptors) down-regulation and desensitization may prevent in vivo the down-regulation ofopioid receptors and their functional uncoupling from G-proteins. In brain, one can assume the existence of an equilibrium state between different receptors sharing similar functional activities on the same neural pathway. In this context, the cellular adaptations to the chronic presence of agonists could represent a coordinate reaction between receptor-effector systems, in which ␣ 2A -adrenoceptors display in frontal cortex higher sensitivity than -opioid receptors to the intracellular mechanisms promoting down-regulation. Obviously, this must mean that in cell cultures, an in vitro system expressing a limited number of different receptor structures, the equilibrium state between receptors changes with respect to that in brain. Thus, in the absence of ␣ 2A -adrenoceptor expression, the chronic exposure to opioid agonists might result in a selective loss of -opioid receptor binding sites and/or in a receptor uncoupling from the transduction pathways activated by this receptor type.
